Corpus Intelligence IC Memo — SAN MATEO MEDICAL CENTER 2026-04-26 19:06 UTC
IC Memo — SAN MATEO MEDICAL CENTER
Investment Committee Memorandum | CA | 69 beds | Grade C | EBITDA uplift $12.5M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

SAN MATEO MEDICAL CENTER

CCN 050113 | SAN MATEO, CA | 69 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

SAN MATEO MEDICAL CENTER is a 69-bed under-performing / distressed in SAN MATEO, CA with $169.7M in net patient revenue and a -100.0% operating margin. The hospital serves a payer mix of 6.3% Medicare, 10.4% Medicaid, and 83.3% commercial.

Thesis: Turnaround. Our ML models identify $12.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -100.0% to -147.6% (+736bps).

Net Revenue HCRIS$169.7M
Current EBITDA COMPUTED$-262.8M
Operating Margin COMPUTED-100.0%
Occupancy HCRIS53.9%
Revenue / Bed COMPUTED$2.5M
Net-to-Gross HCRIS28.6%
Distress Probability ML45.8%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
137
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of -100.0% places it below the state median. Among 137 size-comparable peers (34-138 beds), the median margin is -4.9%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (34-138), prioritizing same-state peers. 137 hospitals in the comp set.

HospitalStateBedsRevenueMargin
SAN MATEO MEDICAL CENTER (Target)CA69$169.7M-100.0%
CONTRA COSTA REGIONAL MEDICAL CA124$595.0M-29.2%
RANCHO LOS AMIGOS NATL.REHAB.CCA83$512.6M41.9%
USC NORRIS CANCER HOSPITALCA60$468.7M19.1%
EDEN MEDICAL CENTERCA126$389.8M2.7%
SUTTER SANTA ROSA REGIONAL HOSCA124$374.4M-0.2%
DESERT VALLEY HOSPITAL INC.CA138$350.1M5.4%
ST. JOSEPH HOSPITAL - EUREKACA132$331.9M-16.9%
KFH - FREMONTCA100$296.2M-6.6%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $12.5M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$3.6M+210bp18mo
Cost to Collect4.5%2.5%$3.4M+200bp12mo
Denial Rate Reduction12.0%6.5%$3.4M+198bp12mo
A/R Days Reduction5200.0%3800.0%$2.1M+122bp9mo
Clean Claim Rate88.0%96.0%$109K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$3.6M
Cost to Collect
$3.4M
Denial Rate Reduction
$3.4M
A/R Days Reduction
$2.1M
Clean Claim Rate
$109K
Total EBITDA Uplift$12.5M
Current EBITDA$-262.8M
+ RCM Uplift+$12.5M
Pro Forma EBITDA$-250.3M
Current Margin-100.0%
Pro Forma Margin-147.6%
WC Released (1x)$6.5M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-404.4M$-1.61B0.00x-100.0%
Base (11x exit)10.0x11.0x$-404.4M$-1.90B0.00x-100.0%
Bull Case9.0x11.0x$-363.9M$-1.99B0.00x-100.0%
Bull (12x exit)9.0x12.0x$-363.9M$-2.28B0.00x-100.0%
Bear Case11.0x10.0x$-444.8M$-1.54B0.00x-100.0%
Bear (11x exit)11.0x11.0x$-444.8M$-1.84B0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 137 hospitals with 34-138 beds
  • Same-state prioritization (n=138)
  • Comp margins: P25=-20.7% / P50=-4.9% / P75=2.7%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.